Marshall Wace North America’s Akero Therapeutics AKRO Stock Holding History

Marshall Wace North America’s Portfolio AKRO Stock Details AKRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-86,123	Closed	-$2.5M	–	1418
2021 Q1	$2.5M	Sell	86,123 -68,565	-44%	-$2.08M	0.01%	760
2020 Q4	$3.99M	Hold	154,688	–	–	0.02%	591
2020 Q3	$4.76M	Buy	+154,688	New	+$5.41M	0.03%	406
2020 Q2	–	Sell	-2,939	Closed	-$62K	–	1132
2020 Q1	$62K	Buy	+2,939	New	+$63K	﹤0.01%	1055
2019 Q3	–	Sell	-54,304	Closed	-$1.04M	–	1292
2019 Q2	$1.04M	Buy	+54,304	New	+$1.03M	0.01%	738

Other funds holding AKRO

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

YCM

Yiheng Capital Management San Francisco, California $231M AUM 29.07% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Marshall Wace North America's AKRO Position: Q2 2021 in Review

Marshall Wace North America sold out of Akero Therapeutics (AKRO) in Q2 2021, closing a stake of 86,123 shares — an estimated $2.5M sold.

Marshall Wace North America first reported a position in AKRO in Q2 2019 and held it in 5 quarters. The position peaked at $4.76M in Q3 2020. 97 funds tracked by Wall St. Rank hold AKRO as of Q2 2021.

Marshall Wace North America reported no remaining Akero Therapeutics position as of Q2 2021 after selling out during the quarter.
Marshall Wace North America sold 86,123 Akero Therapeutics shares in Q2 2021, an estimated $2.5M.
Marshall Wace North America first reported a position in Akero Therapeutics in Q2 2019 and held it in 5 quarters.
Marshall Wace North America's Akero Therapeutics position peaked at $4.76M in Q3 2020.
97 funds tracked by Wall St. Rank held Akero Therapeutics as of Q2 2021.

Based on Marshall Wace North America's 13F filing for Q2 2021, filed 13 Aug 2021.